Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.47 |
| ▸ | PDE4A | P27815 | 10/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009756 | 0.85 | PDE4D (0.53) | PDE4D | |
| SCHEMBL986720 | 0.84 | PDE4D (0.44) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3122756 | 0.82 | PDE4B (0.45) | PDE4DPDE4BPDE4APDE4CEPHA2 | |
| SCHEMBL984917 | 0.81 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL986983 | 0.81 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL986982 | 0.81 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CIDH1 | |
| SCHEMBL3118081 | 0.81 | PDE4B (0.41) | PDE4DPDE4BPDE4APDE4CEPHA2 | |
| SCHEMBL3132677 | 0.80 | PDE4B (0.41) | PDE4DPDE4BPDE4APDE4CEPHA2 | |
| SCHEMBL6876003 | 0.77 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CEPHA2 | |
| SCHEMBL15763184 | 0.76 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4D 6/4885PDE4B 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.